TeamDrive
RUS

RusnanoMedInvest

www.rmi.com.ru

RusnanoMedInvest (a subsidiary of RUSNANO) - was founded in March 2012 and is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology. Initial funding - $ 380 mln.

The key strategic objective of RusnanoMedInvest is to create a Russian-domiciled locus of world-class expertise in venture capital fundraising, deal origination and execution in Life Sciences, with a clear focus on innovative pharmaceutical projects backed by sustainable, cutting edge technologies.

Together with U.S. life sciences venture firm Domain Associates LLC, RusnanoMedInvest is now executing a pharmaceutical project to assume not less than 20 innovative molecules to be localized in Russia. Ultimately this will significantly reduce the introduction lead time of new and innovative medicines and medical devices in Russia targeted at delivering significant therapeutic benefits and efficiencies in disease areas that are classified as socially significant complex, poorly treated and widely prevalent diseases in Russia  in cases where no domestically sourced, effective treatment methods are available today.

Media Center

  • 20 July 2018

    Russian drugs with precise delivery system may become available in five years

    A system of intracellular drug delivery was developed at the Institute of Theoretical and Experimental Biophysics (ITEB) of The Russian Academy of Sciences (RAS). This principle is expected to be used to obtain highly effective anti-inflammatory drugs.

  • 19 July 2018

    China will bring down prices for cancer drugs

    China’s state medical insurance administration will start a new round of negotiations with pharmaceutical companies to add more cancer drugs to the insurance list.

  • 18 July 2018

    Russia and Bulgaria signed cooperation agreement

    Last week, on July 10, 2018, in Sofia Vladislav Shestakov – Director of the State Institute of Drugs and Good Practices, Deputy Head of the State GMP Inspectorate met with Professor Assena Stoimenova, Executive Director of the Bulgarian Drug Agency (Medicines Agency of the Bulgarian Health Ministry).

  • 18 July 2018

    EMA Relocation Countdown: Some Industry Viewpoints

    July 1, 2018 marked the start of the six-month countdown to the European Medicines Agency (EMA) relocation of its operations to Amsterdam. Worryingly, there remains little guidance or clarity from the EMA as to the implications of the move, and Brexit, on the pharma industry.

Read more